Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: A scandinavian multicenter study

Circulation: Cardiovascular Interventions

Volumn 4, Issue 3, 2011, Pages 256-265

  Jensen, Morten Kvistholm ^a   Almaas, Vibeke Marie ^b   Jacobsson, Linda ^c   Hansen, Peter Riis ^d   Havndrup, Ole ^a   Aakhus, Svend ^b   Svane, Bertil ^c   Hansen, Thomas Fritz ^d   Køber, Lars ^a   Endresen, Knut ^b   Eriksson, Maria J ^c   Jørgensen, Erik ^a   Amlie, Jan Peder ^b   Gadler, Fredrik ^c   Bundgaard, Henning ^a  

^a Rigshospitalet   (Denmark)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cardiomyopathy hypertrophic; Left ventricular outflow obstruction; Multicenter study; Percutaneous transluminal septal myocardial ablation; Survival; Treatment outcome

Indexed keywords

ABLATION THERAPY; ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; ASYSTOLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COMPLETE HEART BLOCK; CORONARY ARTERY PERFORATION; CORONARY ARTERY SPASM; CORONARY ARTERY THROMBOSIS; DIABETES MELLITUS; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART BLOCK; HEART DEATH; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART TAMPONADE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HEMOPERICARDIUM; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; HYPOTENSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL SEPTAL MYOCARDIAL ABLATION; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCANDINAVIA; SURVIVAL RATE; SYNCOPE; VALSALVA MANEUVER; VALVULAR HEART DISEASE;

AGE FACTORS; AGED; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; FEMALE; HEMODYNAMICS; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84860390487     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.110.959718     Document Type: Article

References (32)

1. Shah JS, Esteban MT, Thaman R, Sharma R, Mist B, Pantazis A, Ward D, Kohli SK, Page SP, Demetrescu C, Sevdalis E, Keren A, Pellerin D, McKenna WJ, Elliott PM. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart. 2008;94:1288-1294.
2. Elliott PM, Gimeno JR, Tome MT, Shah J, Ward D, Thaman R, Mogensen J, McKenna WJ. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006;27:1933-1941. (Pubitemid 44297366)
3. Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Losse B, Schwartzkopff B. Management of symptomatic hypertrophic obstructive cardiomyopathy-long-term results after surgical therapy. Thorac Cardiovasc Surg. 1999;47:213-218. (Pubitemid 29470003)
4. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Dan-ielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardio-myopathy. J Am Coll Cardiol. 2005;46:470-476. (Pubitemid 41040288)
5. Dearani JA, Ommen SR, Gersh BJ, Schaff HV, Danielson GK. Surgery insight: septal myectomy for obstructive hypertrophic cardiomyopa-thy-the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med. 2007; 4:503-512. (Pubitemid 47321549)
6. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, Siu S, Ralph-Edwards A, Rakowski H. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005;111:2033-2041. (Pubitemid 40577897)
7. Smedira NG, Lytle BW, Lever HM, Rajeswaran J, Krishnaswamy G, Kaple RK, Dolney DO, Blackstone EH. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2008;85:127-133. (Pubitemid 350265812)
8. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211-214.
9. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol. 2007;96:864-873. (Pubitemid 350164933)
10. Kuhn H, Lawrenz T, Lieder F, Leuner C, Strunk-Mueller C, Obergassel L, Bartelsmeier M, Stellbrink C. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol. 2008;97:234-243 (Pubitemid 351464524)
11. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, III, Spirito P, Ten Cate FJ, Wigle ED. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42: 1687-1713.
12. Fernandes VL, Nielsen C, Nagueh SF, Herrin AE, Slifka C, Franklin J, Spencer WH III. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. J Am Coll Cardiol Cardiovasc Interv. 2008;1:561-570.
13. Seggewiss H, Rigopoulos A, Welge D, Ziemssen P, Faber L. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol. 2007;96:856-863. (Pubitemid 350164934)
14. Leonardi RA, Kransdorf EP, Simel DL, Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010;3:97-104.
15. Faber L, Seggewiss H, Fassbender D, Bogunovic N, Strick S, Schmidt HK, Gleichmann U. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography]. Z Kardiol. 1998;87:191-201. (Pubitemid 28292035)
16. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol. 1998;31:252-258.
17. Jensen MK, Havndrup O, Pecini R, Dalsgaard M, Hassager C, Helqvist S, Kelbaek H, Jorgensen E, Kober L, Bundgaard H. Comparison of Valsalva manoeuvre and exercise in echocardiographic evaluation of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Eur J Echocardiogr. 2010;11:763-769.
18. Statistics Denmark. www.statbank.dk. Accessed May 15, 2009.
19. Statistisk Årbog 2010. http://www.dst.dk/pukora/epub/upload/15197/ headword/dk/431.pdf. Accessed June 9, 2010.
20. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE Multinational Database of 19030 patients. Eur J Cardiothorac Surg. 1999;15:816-822; discussion 822-813.
21. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, Hodge DO, Schaff HV, Holmes DR Jr. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008; 118:131-139.
22. Brown ML, Schaff HV, Dearani JA, Li Z, Nishimura RA, Ommen SR. Relationship between left ventricular mass, wall thickness, and survival after subaortic septal myectomy for hypertrophic obstructive cardiomy-opathy. J Thorac Cardiovasc Surg. 2011;141:439-443.
23. van der LC, Scholzel B, ten Berg JM, Geleijnse ML, Idzerda HH, van Domburg RT, Vletter WB, Serruys PW, Ten Cate FJ. Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation. Am J Cardiol. 2008;101:1315-1320.
24. Veselka J, Duchonova R, Palenickova J, Zemanek D, Tiserova M, Lin-hartova K, Cervinka P. Impact of ethanol dosing on the long-term outcome of alcohol septal ablation for obstructive hypertrophic cardio-myopathy: a single-center prospective, and randomized study. Circ J. 2006;70:1550-1552. (Pubitemid 44819868)
25. Bhagwandeen R, Woo A, Ross J, Wigle ED, Rakowski H, Kwinter J, Eriksson MJ, Schwartz L. Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre. Can J Cardiol. 2003;19:912-917. (Pubitemid 37069315)
26. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Mueller C, Kuhn H. Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients. Heart. 2004;90:638-644. (Pubitemid 38668537)
27. Kim JJ, Lee CW, Park SW, Hong MK, Lim HY, Song JK, Jin YS, Park SJ. Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol. 1999;83:1220-1223. (Pubitemid 29183921)
28. Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;41:315-321. (Pubitemid 36092203)
29. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. Int J Cardiol. 2007;119:163-167. (Pubitemid 46818511)
30. El-Jack SS, Nasif M, Blake JW, Dixon SR, Grines CL, O'Neill WW. Predictors of complete heart block after alcohol septal ablation for hyper-trophic cardiomyopathy and the timing of pacemaker implantation. J Interv Cardiol. 2007;20:73-76. (Pubitemid 46161069)
31. Veselka J, Zemanek D, Tomasov P, Duchonova R, Linhartova K. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective. Heart Vessels. 2009;24:27-31.
32. Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interv Cardiol. 2006;19:319-327. (Pubitemid 44185823)